Kilspax (Phloroglucinol Dihydrate)

Phloroglucinol works by blocking calcium entry into smooth‑muscle cells, which lowers intracellular calcium levels and prevents muscle contraction. This direct action relaxes the smooth muscle of the gastrointestinal, biliary, urinary and uterine tracts, reducing spasm‑induced discomfort.

The dosage of Kilspax is determined by the prescribing healthcare professional based on the patient’s condition, severity of symptoms and individual response. Patients should follow the exact regimen provided by their prescriber and not adjust the dose on their own.

Safety data for phloroglucinol in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under medical supervision.

To request Kilspax, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kilspax (phloroglucinol) is a direct smooth‑muscle relaxant that does not possess anticholinergic activity, unlike agents such as hyoscine butylbromide. This can result in fewer anticholinergic side effects such as dry mouth or blurred vision, while providing comparable relief of spasm‑related pain.

Kilspax should be stored below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity to maintain its stability.

Kilspax is taken orally, usually with a glass of water. It can be taken with or without food, unless the prescriber advises otherwise. Swallow the tablet whole; do not crush or chew unless instructed by a healthcare professional.

The most serious risks include severe allergic reactions such as rash, urticaria or anaphylaxis, and marked hypotension that may lead to dizziness or fainting. Patients should seek immediate medical attention if they experience any signs of a severe reaction.

Kilspax should be avoided in individuals with known hypersensitivity to phloroglucinol or any of its excipients, and in patients with severe renal or hepatic impairment unless specifically directed by a physician. Caution is also advised for those taking multiple antispasmodic agents.